Synairgen plc

Equities

SNG

GB00B0381Z20

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:26 2024-03-18 pm EDT 5-day change 1st Jan Change
5.495 GBX -1.08% Intraday chart for Synairgen plc -4.35% -8.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FTSE 100 Finishes Slightly Lower After Steady Session DJ
Synairgen names Phytome's Joseph Colliver as CFO AN
Biotech Company Synairgen Names New CFO MT
Synairgen plc Announces Executive Changes CI
Synairgen plc Announces Board Changes CI
Synairgen promotes Marcin Mankowski to chief medical officer AN
Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer CI
Synairgen narrows interim loss on reduced R&D spending AN
Earnings Flash (SNG.L) SYNAIRGEN Posts H1 Loss GBX-2.36 MT
Synairgen plc Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Synairgen loss narrows; aims to develop SNG001 AN
Earnings Flash (SNG.L) SYNAIRGEN Reports FY22 Loss GBX-8.76 MT
Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TRADING UPDATES: SulNOx raises funds; Synairgen shares trial results AN
Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research CI
Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee CI
Synairgen Unveils Promising Phase Two Trial Results for Investigational Treatment Against COVID-19 MT
Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health/ Aids Clinical Trials Group-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19 CI
Earnings Flash (SNG.L) SYNAIRGEN Posts H1 Loss GBX-6.16 MT
Synairgen plc Announces Changes to Its Board CI
Synairgen plc Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022 CI
Synairgen's SNG001 Reduces Long COVID-19 Symptoms In Follow-up Visits After Late-stage Trial MT
Synairgen Announces Positive Findings from Analysis of Lung Samples from the SG015 Trial of SNG001 in Virally Infected COPD Patients CI
Synairgen Surges 10% After Analysis Finds Antiviral Inhaler Accelerates Virus Removal in Lungs MT
Chart Synairgen plc
More charts
Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company; Synairgen Inc. and Synairgen Research (Ireland) Limited. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.055 GBP
Average target price
0.4 GBP
Spread / Average Target
+627.93%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Synairgen plc - London S.E.
  4. News Synairgen plc
  5. Synairgen's SNG001 Reduces Long COVID-19 Symptoms In Follow-up Visits After Late-stage Trial